Retrospective-perspective Observational Cohort Study on Toxicity and Efficacy of Radiotherapy in Pediatric and Adult Patients With Pediatric Histology Treated at the Pediatric Radiotherapy of the CRO in Aviano

Launched by CENTRO DI RIFERIMENTO ONCOLOGICO - AVIANO · Oct 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of radiotherapy, a common treatment for cancer, on both children and adults who have certain types of tumors typically seen in younger patients. The main goal is to understand the short- and long-term side effects (known as toxicity) that may occur after treatment, especially since some of these can develop many years later. Researchers are particularly interested in how different factors, like age and the specific types of tumors, influence these outcomes.

To be eligible for the study, patients must be either children, teenagers, or young adults under 25 years old, or adults aged 25 and older who have specific childhood-type cancers. Participants should have received their radiation treatment at the Pediatric Radiotherapy Unit in Aviano between certain dates. Those who join the study will help researchers gather important information about the safety and effectiveness of radiotherapy over time, which can lead to better treatment strategies for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pediatric, adolescent, and young adult (\<25 years old) patients with malignant neoplasm
• • Adult patients (≥25 years) with malignant neoplasm with histology typical of pediatric age but rarely also found in adults and typically treated wherever possible in pediatric protocols (mainly: Central nervous system malignancies such as medulloblastomas and other embryonal tumors, ependymomas, and germ cell tumors; soft tissue and bone sarcomas such as rhabdomyosarcomas and Ewing's sarcomas; nephroblastomas; neuroblastomas)
• • Underwent radiation treatment at the Pediatric Radiotherapy Unit of the CRO in Aviano
• • Between October 24, 1991, and September 30, 2020, with regard to the retrospective phase of the study, and between October 1, 2020, and September 30, 2030, with regard to the prospective phase of the study
• • And who provide informed consent to the study if alive and traceable at the time of enrollment with regard to the retrospective phase of the study and necessarily with regard to the prospective phase. Regarding deceased or alive but untraceable patients enrollable in the retrospective phase of the study, since these are patients who had already given consent to data processing at the time of the radiation therapy being analyzed and registration/enrollment in any specific treatment/research protocols, no new consent is required for the study
• Exclusion Criteria:
• • - Anything not covered in the inclusion criteria